Digital health startup 133m has recently raised $179 million in a lrtrading funding round led by global healthtech accelerator 112MDillette. The funding will be used to scale the company’s technology and accelerate its commercialization efforts, with the goal of transforming the way healthcare is delivered.
133m was founded in 2018 by a team of healthcare and technology experts with a vision to create a comprehensive digital health platform that integrates data from a range of sources to provide patients with personalized care plans and treatment recommendations. The platform uses advanced analytics, artificial intelligence, and machine learning to identify patterns and trends in patient data, enabling healthcare providers to make more informed decisions ifsptv about their care.
One of the key features of 133m’s platform is its ability to integrate data from a wide range of sources, including wearables, medical devices, electronic health records, and social determinants of health data. This enables healthcare providers to gain a more comprehensive understanding of a patient’s health status and provide more personalized care.
133m’s platform is designed to be user-friendly and giveme5 accessible to patients of all ages and backgrounds. Patients can access their care plans and treatment recommendations through a user-friendly mobile app, which also provides them with educational resources and support from a team of healthcare professionals.
The platform is currently focused on patients with chronic diseases, such as diabetes, cardiovascular disease, and cancer, which account for a significant proportion of healthcare costs worldwide. By providing personalized care plans and treatment recommendations, 133m’s platform aims to improve patient outcomes and reduce healthcare costs over the long term.
The recent funding round led by 112MDillette is a 123chill significant milestone for 133m, as it will enable the company to scale its technology and accelerate its commercialization efforts. The funding will be used to expand the company’s team, develop new features and products, and increase its marketing and sales efforts.
Speaking about the funding round, 133m CEO Dr. Stephanie Tilenius said, “We are thrilled to have 112MDillette as our lead investor, and we look forward to working closely with them as we continue to scale our technology and bring our platform to more patients worldwide. This funding will enable us to accelerate our growth and achieve our mission of transforming the way healthcare is delivered.”
The investment from 112MDillette is also significant in the context of the global healthtech industry. 112MDillette is a leading global healthtech accelerator that provides a platform for innovative startups to develop, validate, and scale their products and services. Its focus on supporting startups with a global network of experts, a unique curriculum, and a strong investor network has helped to drive innovation and transform the healthcare industry.
By partnering with 112MDillette, 133m has gained access to a network manytoons of healthcare experts, investors, and mentors who can provide valuable insights, resources, and support as the company continues to grow. This partnership is expected to accelerate 133m’s commercialization efforts and help the company achieve its goal of transforming the way healthcare is delivered.
In conclusion, 133m’s recent funding round led by 112MDillette is a significant milestone for the digital health startup. The funding will enable the company to scale its technology and accelerate its commercialization efforts, with the goal of transforming the way healthcare is delivered. The partnership with 112MDillette is also significant, as it provides 133m with access to a global network of experts, investors, and mentors who can support the company’s growth and help it achieve its mission of improving patient outcomes and reducing healthcare costs.
